亚盛医药-B:25 年销售收入有望翻倍 上涨 3.83%

和讯网
03 Feb

【亚盛医药-B早盘上涨 3.83%,现报 35.25 港元,成交额 1729.38 万港元】东吴证券发布研报称,亚盛医药致力于血液瘤小分子药物开发,管线专注细胞凋亡和激酶抑制剂。其中,耐立克已在国内获批上市,海外权益授权武田,开启重磅全球合作。另一款核心产品 APG-2575 已在国内递交上市申请,海外 III 期临床推进中。1 月 24 日挂牌纳斯达克,赴美上市开启国际化新篇章。该行续指,耐立克...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10